Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

Ixazomib-lenalidomide-dexamethasone in routine clinical practice

Written by Roman Hájek

The latest Publication Perspective from the Video Journal of Biomedicine summarizes a recent article published in Future Oncology Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma’. In this video publication, the lead author, Roman Hájek provides a summary of the article, which looks at the effectiveness and safety of ixazomib-lenalidomide-dexamethasone in routine clinical practice.

Original publication:

Hájek R, Minařík J, Straub J et al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol.  doi:10.2217/fon-2020-1225 (2021) [Epub ahead of print]

About the Video Journal of Biomedicine:

The Video Journal of Biomedicine, published by Future Medicine, provides the missing link between high-quality research information and its intended audience, be that fellow experts, researchers in other fields, students and trainees, or the general public (including patients and caregivers). Through concise, high-quality videos, with the author on screen or via voice-over animation, researchers are able to personally explain their work, highlighting its importance, placing it in context, and discussing future implications.

Visit the Video Journal of Biomedicine to find out more>>

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Oncology Central or Future Science Group.